CoChat

Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double‐blind, placebo‐controlled trial

Open access
Satoh, J., Yagihashi, S., Baba, M., Suzuki, M., Arakawa, A., Yoshiyama, T., Shoji, S. · 2011 · Diabetic Medicine
Cited by 152

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 28, 109–116 (2011) Aims To evaluate the efficacy, safety and pharmacokinetics of pregabalin in treating neuropathic pain associated with diabetic peripheral neuropathy in Japanese patients. Methods A randomized, double‐blind, placebo‐controlled, multicentre 14 week clinical trial was conducted. Japanese patients with diabetic peripheral neuropathy (n = 317) were randomized to receive placebo or pregabalin at 300 or 600 mg/day. The primary efficacy measure was a change of mean pain score from baseline to end‐point from patients’ daily pain diaries. Results Significant reductions in pain were observed in patients treated with pregabalin at 300 and 600 mg/day vs. placebo (P < 0.05). Improvements in weekly pain scores were observed as early as week 1 and were sustained throughout the study period (300 and 600 mg/day difference from placebo at study end‐point, –0.63 and –0.74, respectively). Pregabalin produced significant improvements in weekly sleep interference scores, the short‐form McGill Pain Questionnaire, the Medical Outcomes Study–Sleep Scale, the 36‐item Short‐Form Health Survey scale, and the Patient and Clinical Global Impression of Change. Patient impressions of numbness, pain and paraesthesia were also significantly improved. Regarding treatment responders, 29.1 and 35.6% of patients treated with 300 and 600 mg/day, respectively, reported ≥50% improvement in mean pain scores (vs. 21.5% for placebo). Pregabalin was well tolerated; somnolence (26%), dizziness (24%), peripheral oedema (13%) and weight gain (11%) were the most common adverse events and generally were reported as mild to moderate. Conclusions Pregabalin was effective in reducing pain and improving sleep disturbances due to pain, and was well tolerated in Japanese patients with painful DPN.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2010.03152.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 152

Metadata

Authors
Satoh, J., Yagihashi, S., Baba, M., Suzuki, M., Arakawa, A., Yoshiyama, T., & Shoji, S.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2010-12-19
Volume
28
Issue
1
Pages
109-116
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1845521331
Cited by
152
References
4
FWCI
6.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/j.1464-5491.2010.03152.x
The paper
Satoh, J., Yagihashi, S., Baba, M., Suzuki, M., Arakawa, A., Yoshiyama, T., & Shoji, S. (2011). Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double‐blind, placebo‐controlled trial. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2010.03152.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.